{
    "clinical_study": {
        "@rank": "61980", 
        "arm_group": {
            "arm_group_label": "PL225B", 
            "arm_group_type": "Experimental", 
            "description": "Patients will receive study drug on a daily basis until disease progression or unacceptable toxicity in sequential cohorts following accelerated titration design."
        }, 
        "brief_summary": {
            "textblock": "Clinical study of oral IGF-1R inhibitor PL225B in subjects with advanced refractory solid\n      tumors. The primary objective is to determine the maximum tolerated dose and dose limiting\n      toxicity (ies) of oral IGF-1R inhibitor PL225B in subjects with advanced refractory solid\n      tumors."
        }, 
        "brief_title": "Clinical Study of Oral IGF-1R Inhibitor in Subjects With Advanced Refractory Solid Tumors", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced Refractory Solid Tumors", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "An open label multicentre Phase 1 study of oral IGF-1R inhibitor PL225B in subjects with\n      advanced refractory solid tumors. This is a dose-finding trial using the modified\n      Accelerated Titration Design with 3 new subjects per cohort and 100% dose increments in the\n      accelerated phase followed by standard phase with 40% dose increments.Subjects will receive\n      study drug on a daily basis for twenty-one (21) days according to the dose and schedule\n      specified for a particular cohort of therapy. Toxicity profile of the drug will be assessed\n      during Cycle 1 of subject treatment in each cohort for determination of Maximum Tolerated\n      Dose (MTD) according to the schedule given below."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects having histologically and/or cytologically confirmed non-haematological\n             malignancy that is metastatic or unresectable and for which standard curative or\n             palliative treatment does not exist or is no longer effective\n\n          -  Subjects should have measurable or evaluable disease\n\n          -  Subjects of either sex, of all races and ethnic groups, and \u226518 years of age\n\n          -  ECOG (Eastern Cooperative Oncology Group) performance status 0-1\n\n          -  Subjects with life expectancy of at least 4 months\n\n          -  Subjects with fasting plasma glucose \u2264 125 mg/dL and HbA1c < 6.5 % at screening\n             Subjects with fasting plasma glucose \u2264150 mg/dL and HbA1c \u2264 7.0 % at screening for\n             the Diabetes Expansion Cohort.\n\n          -  For the Diabetes Expansion Cohort - Subjects with known history of type 2 diabetes\n             mellitus that are well-controlled on a stable dose of oral anti-diabetic agents such\n             as metformin and/or sulfonylureas for 4 weeks prior to screening.\n\n          -  Subjects must have normal organ and marrow function as defined below:\n\n               1. Absolute neutrophil count \u2265 1500/cmm\n\n               2. Platelets \u2265 100,000/cmm\n\n               3. Total bilirubinwithin normal limits of the institution\n\n               4. AST/ALT \u2264 2.5 X institutional upper limit of normal (ULN) or \u2264 5 X institutional\n                  upper limit of normal (ULN) in the presence of liver metastases\n\n               5. Creatinine \u2264 1.5 X institutional upper limit of normal (ULN)\n\n          -  Subjects willing for repeat oral dosing and follow-up, including pharmacokinetic\n             sampling\n\n          -  Women of childbearing potential and men willing to agree to use adequate\n             contraception (hormonal or barrier method of birth control; abstinence) prior to\n             study entry, during the duration of study participation and for at least 4 weeks\n             after withdrawal from the study, unless they are surgically sterilised\n\n          -  Ability to understand and the willingness to provide a written informed consent\n             document\n\n        Exclusion Criteria\n\n          -  Subjects who have received any prior chemotherapy, radiotherapy, biologic/targeted\n             anti-cancer therapy or surgery within 4 weeks (6 weeks for monoclonal antibodies,\n             radioactive monoclonal antibodies or any radio- or toxin- immunoconjugates) before\n             the first study drug administration and have not recovered (to AEs <  Grade 2) from\n             the toxic effects from any prior therapy\n\n          -  Subjects having received any other investigational agents within 4 weeks prior to the\n             first study drug administration and have not recovered completely (to AEs <  Grade 2)\n             from the side effects of the earlier investigational agent\n\n          -  Subjects with documented history of diabetes mellitus except for the Diabetes\n             Expansion Cohort\n\n          -  For the Diabetes Expansion Cohort - Subjects who have type 1 diabetes mellitus,\n             maturity onset diabetes of the young, hyperglycemia due to reasons other than type 2\n             diabetes mellitus.\n\n          -  For the Diabetes Expansion Cohort - Subjects who currently require insulin,\n             thiazolidinediones, dual proliferator-activated receptors (PPAR) agonists,\n             glucagon-like peptide (GLP-1) analogues, dipeptidyl peptidase (DPP-IV) inhibitors or\n             have received the same in the 4 weeks prior to screening.\n\n          -  Subjects with known complications of diabetes like diabetic nephropathy or diabetic\n             retinopathy\n\n          -  Subjects with known brain metastases\n\n          -  Subjects with gastrointestinal abnormalities including inability to take oral\n             medication, malabsorption or other conditions like chronic inflammatory bowel disease\n             that may affect absorption.\n\n          -  Subjects with a history of myocardial infarction or uncontrolled cardiac dysfunction\n             during the previous 6 months\n\n          -  Subjects with baseline QTc interval >470 msec at screening\n\n          -  Subjects on warfarin. Prophylactic anticoagulation with low molecular weight heparin\n             is allowed\n\n          -  Subjects with history of anaphylaxis or angioedema, bronchial asthma, peptic ulcer\n             and clinically significant food or drug allergy\n\n          -  Subjects with uncontrolled intercurrent illness including, but not limited to ongoing\n             or active infection, symptomatic congestive heart failure, unstable angina pectoris,\n             cardiac arrhythmia, or psychiatric illness/social situations that would limit\n             compliance with study requirements\n\n          -  Women who are pregnant or nursing\n\n          -  Subjects with known seropositivity to human immunodeficiency virus (HIV), positive\n             for Hepatitis B, positive for Hepatitis C (antigen positive), or known hepatic\n             cirrhosis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01779336", 
            "org_study_id": "PL225B/71/11"
        }, 
        "intervention": {
            "arm_group_label": "PL225B", 
            "description": "Patients will receive study drug on a daily basis for twenty-one (21) days according to the dose and schedule specified for a particular cohort of therapy.\nThis 21 day administration will define a treatment cycle.\nPatients may receive consecutive treatment cycles until evidence of disease progression, intolerance of therapy, or withdrawal from the protocol as specified.", 
            "intervention_name": "PL225B", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Advanced Refractory Solid Tumors", 
        "lastchanged_date": "January 31, 2014", 
        "location": [
            {
                "contact": {
                    "email": "elkhouei@usc.edu", 
                    "last_name": "Dr Anthony El-Khoueir, MD", 
                    "phone": "323-865-3967"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "USC Norris Comprehensive Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Dr Anthony El-Khoueiry, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ajayonco@hotmail.com", 
                    "last_name": "Dr. Ajay Mehta, MBBS, MS, UICC", 
                    "phone": "91-712-2520956"
                }, 
                "facility": {
                    "address": {
                        "city": "Nagpur", 
                        "country": "India", 
                        "state": "Maharashtra", 
                        "zip": "440010"
                    }, 
                    "name": "Central India Cancer Research Institute"
                }, 
                "investigator": {
                    "last_name": "Ajay Mehta, MBBS, MS, UICC", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "drraj@manavatacancercentre.com", 
                    "last_name": "Dr Rajnish Nagarkar", 
                    "phone": "02532592666"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashik", 
                        "country": "India", 
                        "state": "Maharashtra", 
                        "zip": "422004"
                    }, 
                    "name": "Curie Manavata Cancer Centre"
                }, 
                "investigator": {
                    "last_name": "Dr Rajnish Nagarkar", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "minishjain009@gmail.com", 
                    "last_name": "Dr Minish Jain, MD", 
                    "phone": "+912066455604"
                }, 
                "facility": {
                    "address": {
                        "city": "Pune", 
                        "country": "India", 
                        "state": "Maharashtra", 
                        "zip": "411001"
                    }, 
                    "name": "Ruby Hall Clinic"
                }, 
                "investigator": {
                    "last_name": "Dr Minish Jain Jain", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kkratnam@gmail.com", 
                    "last_name": "Dr. Krishna Kumar Ratnam, MBBS, MD, DM", 
                    "phone": "91-9380417299"
                }, 
                "facility": {
                    "address": {
                        "city": "Madurai", 
                        "country": "India", 
                        "state": "Tamil Nadu", 
                        "zip": "625107"
                    }, 
                    "name": "Meenakshi Mission Hospital and Research Centre"
                }, 
                "investigator": {
                    "last_name": "Dr Krishna Kumar Ratnam, MBBS, MD, DM", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "India"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open Label Multicentre Phase 1 Study of Oral IGF-1R Inhibitor PL225B in Subjects With Advanced Refractory Solid Tumors.", 
        "overall_contact": {
            "email": "alan.hatfield@piramal.com", 
            "last_name": "Dr Alan K Hatfield, MD", 
            "phone": "+91 22 3027 5002", 
            "phone_ext": "5002"
        }, 
        "overall_contact_backup": {
            "email": "sandesh.sawant@piramal.com", 
            "last_name": "Dr Sandesh Sawant, MBBS", 
            "phone": "+91 22 30275130", 
            "phone_ext": "5130"
        }, 
        "overall_official": {
            "affiliation": "University of Southern California", 
            "last_name": "Dr Anthony El-Khoueiry, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "India: Drugs Controller General of India"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Subjects will receive study drug on a daily basis for twenty-one (21) days according to the dose and schedule specified for a particular cohort of therapy.Toxicity profile of the drug will be assessed during Cycle 1 of subject treatment in each cohort for determination of Maximum Tolerated Dose (MTD).", 
            "measure": "Maximum tolerated dose", 
            "safety_issue": "Yes", 
            "time_frame": "End of Cycle 1 (i.e. 21 Days)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01779336"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The toxic effects of the drug would be assessed from adverse events, vital signs and by clinically significant changes in the laboratory evaluations.", 
                "measure": "Number of subject with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Until disease progression or unacceptable toxicity (expected to be 4-6 months)"
            }, 
            {
                "description": "The following PK parameters will be calculated: Cmax (peak plasma concentration), Tmax (time to peak plasma concentration), AUC0-t (area under the plasma concentration curve from time zero to time of last quantifiable concentration), AUC0-12, AUC0-inf  (area under the plasma concentration curve from time zero extrapolated to infinity), percent AUC extrapolated, kel (elimination rate constant), t1/2 (elimination half-life), CL/F (oral clearance), Vz/F (oral apparent volume of distribution) and Racc (accumulation ratio).", 
                "measure": "Pharmacokinetic profile(Cmax,Tmax and AUC)", 
                "safety_issue": "No", 
                "time_frame": "Until disease progression or unacceptable toxicity (expected to be 4-6 months)"
            }, 
            {
                "description": "Plasma samples will be used for analysis of circulating exploratory biomarkers which are likely to change in response to PL225B administration.", 
                "measure": "Activity of PL225B based on selected biomarkers", 
                "safety_issue": "No", 
                "time_frame": "Until disease progression or unacceptable toxicity (expected to be 4-6 months)"
            }, 
            {
                "description": "Evaluation of Response: Clinical responses will be presented patient wise for different dose levels.", 
                "measure": "Objective response", 
                "safety_issue": "No", 
                "time_frame": "Until disease progression or unacceptable toxicity (expected to be 4-6 months)"
            }
        ], 
        "source": "Piramal Enterprises Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Piramal Enterprises Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}